US · GNPX
Genprex, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Austin, TX 78746
- Website
- genprex.com
Price · as of 2024-12-31
$0.92
Market cap 3.26M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | $2,940.00 | ||||
| 2019 | $7,640.00 | ||||
| 2020 | $10,560.00 | ||||
| 2021 | $4,220.00 | ||||
| 2022 | $1,802.00 | ||||
| 2023 | $211.50 | ||||
| 2024 | $17.00 |
AI valuation
Our deep-learning model estimates Genprex, Inc.'s (GNPX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $0.92
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| GNPX | Genprex, Inc. | $0.92 | 3.26M | — | — | — | — | -0.06 | 0.84 | — | 0.01 | — | 0.84 | 0.00% | — | — | -467.24% | -6073.62% | -285.38% | 0.00 | — | 0.83 | 0.64 | 0.08 | -7633.00% | — | -3088.00% | -1259.09% | -6.85 | -4919.06% | 20346.13% | -1312.70% | 20346.13% | 0.01 | 0.01 | — | -69.29 |
| BDRX | Biodexa Pharmaceuticals P… | $1.08 | 90.59K | +65,720% | — | — | — | -0.25 | 0.17 | — | -0.05 | -0.06 | 0.53 | 0.00% | — | — | -88.14% | -269.10% | -45.25% | 0.09 | — | 1.75 | 0.47 | 0.10 | 40524.00% | -10000.00% | 8388.00% | -924.24% | -2.44 | -397.95% | 0.00% | 0.00% | 0.00% | -0.05 | -0.04 | — | -15.86 |
| BIVI | BioVie Inc. | $1.38 | 10.41M | — | — | — | — | -0.15 | 0.14 | — | 0.86 | — | 0.14 | 0.00% | — | — | -101.64% | 8838.56% | -75.01% | 0.02 | -54.30 | 9.10 | 8.64 | 1.01 | -8341.00% | — | -3192.00% | -740.10% | -8.36 | 9307.74% | 0.00% | 0.00% | 0.00% | 0.81 | 0.77 | — | -24.00 |
| CMMB | Chemomab Therapeutics Ltd… | $1.86 | 11.45M | — | — | — | — | -1.60 | 1.66 | — | -0.61 | — | 1.66 | 0.00% | — | — | -91.77% | 1052.79% | -71.64% | 0.02 | — | 4.98 | 4.51 | 0.41 | -6204.00% | — | -3437.00% | -68.89% | -4.80 | 1104.22% | 0.00% | 0.00% | 0.00% | -0.58 | -0.55 | — | -6.50 |
| CNSP | CNS Pharmaceuticals, Inc. | $3.11 | 1.79M | — | — | — | — | -0.68 | 1.63 | — | -0.27 | — | 1.63 | 0.00% | — | — | -1703.39% | 642.50% | -285.68% | 0.05 | -924.50 | 3.43 | 2.91 | 0.41 | -3522.00% | — | 2102.00% | -169.67% | -6.78 | 738.03% | 0.00% | 0.00% | 58.36% | -0.27 | -0.23 | — | -15.99 |
| GRI | GRI Bio, Inc. | $2.55 | 229.07K | +6,695% | — | — | — | -0.02 | 0.04 | — | 0.66 | — | 0.04 | 0.00% | — | — | -238.17% | 791.34% | -166.00% | 0.01 | — | 3.25 | 3.11 | 0.68 | -9212.00% | -10000.00% | 1833.00% | -4086.53% | -3.85 | 673.21% | 0.00% | 0.00% | 1303.49% | 0.66 | 0.78 | — | -12.03 |
| INM | InMed Pharmaceuticals Inc… | $0.85 | 1.54M | +1,918% | +653% | — | — | -0.25 | 0.11 | 0.42 | 1.66 | — | 0.13 | 34.53% | -160.20% | -165.14% | -52.84% | -173.20% | -43.65% | 0.06 | -21.22 | 6.99 | 6.27 | 1.94 | -5848.00% | 750.00% | 1103.00% | -377.16% | -3.10 | -169.90% | 0.00% | 0.00% | 311.23% | 1.52 | 1.55 | -2.43 | -10.26 |
| JAGX | Jaguar Health, Inc. | $0.89 | 1.93M | +7,724% | +550% | — | — | -0.11 | 0.58 | 0.36 | -0.89 | — | -0.38 | 83.27% | -263.76% | -329.30% | -637.50% | -86.37% | -74.93% | 5.01 | -133.47 | 1.63 | 0.49 | -0.78 | -9513.00% | 1975.00% | -1091.00% | -697.04% | -1.49 | -82.96% | 0.00% | 0.00% | 49.45% | -1.06 | -1.11 | 2.80 | -10.43 |
| LIMN | Liminatus Pharma, Inc. Cl… | $0.25 | 7.86M | — | — | — | — | — | — | — | — | — | — | 0.00% | — | — | 21.87% | 87.68% | -79.23% | -0.32 | -21.04 | 0.09 | 0.09 | -1.57 | 16667.00% | — | -713.00% | — | -0.36 | 93.72% | — | 0.00% | — | — | — | — | — |
About Genprex, Inc.
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
- CEO
- Ryan Confer
- Employees
- 15
- Beta
- -0.79
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $0.92) − 1 = — (DCF, example).